The discovery of immune checkpoint inhibitors targeting the PD1/PDL1 axis has transformed cancer treatment paradigms, especially in tumours characterized by high mutational burden or pre-existing immune infiltration [47]. This evidence concerns the gene PDCD1 and cancer.